1. bookVolume 28 (2020): Issue 2 (April 2020)
Journal Details
License
Format
Journal
eISSN
2284-5623
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
access type Open Access

Thromboelastography in pre-surgery monitoring in Hemophilia A with high inhibitor titer: case report and literature review

Published Online: 04 May 2020
Page range: 217 - 224
Received: 10 Nov 2019
Accepted: 05 Mar 2020
Journal Details
License
Format
Journal
eISSN
2284-5623
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
Abstract

The development of factor VIII inhibitors (allo-antibodies) continues to be a major complication in the management of severe forms of hemophilia A, especially as far as treatment and treatment response monitoring is concerned. The need to implement a reliable laboratory assay is all the more obvious if major surgery occurs, when conventional tests (activated partial thromboplastin time APTT, prothrombin time PT, factor VIII level) are of no avail and there is a very fragile balance between bleeding and thrombosis.

We report the case of a 32 year-old patient diagnosed with severe Hemophilia A, referred to the Comprehensive Center for the Diagnosis and Treatment of Hemophilia of the Fundeni Clinical Institute for a multidisciplinary assessment in view of a total left hip arthroplasty due to aseptic necrosis of the femoral neck.

Workup showed a high inhibitor titer (>200 BU). Taking into consideration the interindividual variability of the response to bypassing agents, as well as the bleeding risk associated with a major orthopedic surgery, we used thromboelastography (TEG) to assess the patient’s response to aPCC (activated prothrombin complex concentrate) and rFVIIa (activated recombinant factor VII). The findings helped select the optimal replacement scheme to ensure perioperative hemostasis.

Keywords

1. Tjønnfjord GE, Holme PA. Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in haemophilia patients with high-titer inhibitors. Vasc Health Risk Manag. 2007 Aug; 3(4):527-31.Search in Google Scholar

2. Serban M, Poenaru D, Cernat L, Savescu D, Patrascu J, Schramm W, et al. Global clotting assays - monitoring the effect of by-passing agents in haemophilia patients with inhibitors. Rev Romana Med Lab. 2017 April; 25:135-43. DOI: 10.1515/rrlm-2017-001110.1515/rrlm-2017-0011Search in Google Scholar

3. Meek LS, Batsuli G. Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches. Hematology. 2016 Dec 2; 2016(1):657-62. DOI: 10.1182/asheducation-2016.1.65710.1182/asheducation-2016.1.657614246927913543Search in Google Scholar

4. Holmstro M, Tran HTT, Holme PA. Combined treatment with APCC (FEIBA) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A - a two-centre experience. Haemophilia. 2012 Jul; 18(4):544-9. DOI: 10.1111/j.1365-2516.2012.02748.x10.1111/j.1365-2516.2012.02748.x22348384Search in Google Scholar

5. Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, et al. A randomized comparison of bypassing agents in haemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study Global clotting assays. Blood. 2007 Jan; 109 (2):546-51. DOI: 10.1182/blood-2006-04-01798810.1182/blood-2006-04-01798816990605Search in Google Scholar

6. Gringeri A, Santagostino E, Mannucci PM. Failure of Recombinant Activated Factor VII during Surgery in a Hemophiliac with High-Titer Factor VIII Antibody. Haemostasis. 1991; 21(1):1-4. DOI: 10.1159/00021619410.1159/0002161941907588Search in Google Scholar

7. Young G, Blain R, Nakagawa P, Nugent DJ. Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia. 2006 Nov; 12(6):598-604. DOI: 10.1111/j.1365-2516.2006.01319.x10.1111/j.1365-2516.2006.01319.x17083509Search in Google Scholar

8. Younga G, Ebbesenb LS, Viuffb D, Di Paolac J, Konkled BA, Negriere C, et al. Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial. Blood Coagul Fibrinolysis. 2008 Jun; 19(4):276-82. DOI: 10.1097/MBC.0b013e3283001cdc10.1097/MBC.0b013e3283001cdc18469548Search in Google Scholar

9. Ay Y, Balkan C, Karapinar DY, Akin M, Bilenoglu B, Kavakli K. Feasibility of Using Thrombin Generation Assay (TGA) for Monitoring Bypassing Agent Therapy in Patients with Hemophilia Having Inhibitors. Clin Appl Thromb-Hem. 2013 Jul-Aug; 19(4):389-94. DOI: 10.1177/107602961243861110.1177/107602961243861122395575Search in Google Scholar

10. Furukawa S, Nogami K, Ogiwara K, Yada K, Minami H, Shima M. Systematic monitoring of hemostatic management in hemophilia A patients with inhibitor in the perioperative period using rotational thromboelastometry. J Thromb Haemost. 2015 Jul; 13(7):1279-84. DOI: 10.1111/jth.1298710.1111/jth.1298725903848Search in Google Scholar

11. Kenet G, Stenmo CB, Blemings A, Wegert W, Goudemand J, Krause M, et al. Intra-patient variability of thromboelastographic parameters following in vivo and ex vivo administration of recombinant activated factor VII in haemophilia patients. A multi-centre, randomised trial. Thromb Haemost. 2009 Dec; 103(2):351-9. DOI: 10.1160/TH09-04-021210.1160/TH09-04-021220024491Search in Google Scholar

12. Tran HTT, Sørensen B, Bjørnsen S, Pripp AH, Tjønnfjord GE, Holme PA. Monitoring bypassing agent therapy - a prospective crossover study comparing thromboelastometry and thrombin generation assay. Haemophilia. 2014 Dec; 21(2):1-9. DOI: 10.1111/hae.1257010.1111/hae.1257025521720Search in Google Scholar

13. Dargaud Y, Lambert T, Trossaert T. New advances in the therapeutic and laboratory management of patients with haemophilia and inhibitors. Haemophilia. 2008 Jul; 14(Suppl. 4):20-7. DOI: 10.1111/j.1365-2516.2008.01735.x10.1111/j.1365-2516.2008.01735.x18494689Search in Google Scholar

14. Viuff D, Andersen S, Sørensen BB, Lethagen S. Optimizing thrombelastography (TEG) assay conditions to monitor rFVIIa (NovoSeven®) therapy in haemophilia A patients. Thromb Res. 2010 Aug; 126(2):144-9. DOI: 10.1016/j.thromres.2010.05.00810.1016/j.thromres.2010.05.00820542542Search in Google Scholar

15. Bolliger D, Seeberger MD, Tanaka KA. Principles and Practice of Thromboelastography in Clinical Coagulation Management and Transfusion Practice. Transfus Med Rev. 2012 Jan; 26(1):1-13. DOI: 10.1016/j. tmrv.2011.07.005Search in Google Scholar

16. Chitlur M, Rivard GE, Lillicrap D, Mann K, Shima M, Young G, et al. Recommendations for performing thromboelastography/ thromboelastometry in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014 Jan; 12(1):103-6. DOI: 10.1111/jth.1245810.1111/jth.1245824261669Search in Google Scholar

17. Sørensen B, Ingerslev J. Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography. Haemophilia. 2005 Nov; 11(Suppl. 1):1-6. DOI: 10.1111/j.1365-2516.2005.01156.x10.1111/j.1365-2516.2005.01156.x16219042Search in Google Scholar

18. Pivalizza EG, Escobar MA. Thrombelastography-Guided Factor VIIa Therapy in a Surgical Patient with Severe Hemophilia and Factor VIII Inhibitor. Anesth Analg. 2008 Aug; 107(2):398-401. DOI: 10.1213/ane.0b013e31817b786410.1213/ane.0b013e31817b786418633014Search in Google Scholar

19. Da Luz LT, Nascimento B, Rizoli S. Thrombelastography (TEG): practical considerations on its clinical use in trauma resuscitation. Scand J of Trauma Resusc and Emerg Med. 2013 Apr 16; 21:29. DOI: 10.1186/1757-7241-21-2910.1186/1757-7241-21-29363750523587157Search in Google Scholar

20. Reikvama H, Steienb E, Haugeb B, Lisethc K, Hagencet KG, Størkson R, et al. Thrombelastography. Transfus Apher Sci. 2009 Apr; 40(2):119-23. DOI: 10.1016/j.transci.2009.01.01910.1016/j.transci.2009.01.01919249246Search in Google Scholar

21. Nogami K. The utility of thromboelastography in inherited and acquired bleeding disorders. Br J Haematol. 2016 Jun; 174(4):1-12. DOI: 10.1111/bjh.1414810.1111/bjh.1414827264484Search in Google Scholar

22. Keyand NS, Nelsestuen GL. Views on Methods for Monitoring Recombinant Factor VIIa in Inhibitor Patients. Seminars in Hematology. 2004 Jan; 41(1, Suppl 1):51-4. DOI: 10.1053/j.seminhematol.2003.11.01110.1053/j.seminhematol.2003.11.01114872422Search in Google Scholar

23. Zhou ZY, Hay JH. Efficacy of Bypassing Agents in Patients with Hemophilia and Inhibitors: A Systematic Review and Meta-Analysis. Clin Ther. 2012 Feb; 34(2):434-45. DOI: 10.1016/j.clinthera.2012.01.00110.1016/j.clinthera.2012.01.00122285208Search in Google Scholar

24. Treur MJ, McCracken F, Heeg B, Joshi AV, Botteman MF, deCharro F, et al. Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression. Haemophilia. 2009 Mar; 15(2):420-36. DOI: 10.1111/j.1365-2516.2008.01956.x10.1111/j.1365-2516.2008.01956.x19335751Search in Google Scholar

25. Giangrande PLF, Wilde JT, Madan B, Ludlam CA, Tuddenham EGD. Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven®] in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia. 2009 Mar; 15(2):501-8. DOI: 10.1111/j.1365-2516.2008.01952.x10.1111/j.1365-2516.2008.01952.x19187194Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo